

Press release

IMTM starts clinical Phase I trial with IP10.C8 for topical treatment of Acne

Magdeburg, 03/12/2007 – IMTM GmbH announced the initiation of a Phase I clinical study with the compound IP10.C8. This first randomized, double-blinded, placebo-controlled clinical trial will provide data for the safety, tolerability und pharmacokinetics for topical administration of the first dual peptidase inhibitor derived from the class of PETIR™ substances.

IP10.C8 is under development for the treatment of moderate to severe forms of Acne vulgaris. The substance represents the first candidate of PETIR™ compounds that has been brought into first-in-men studies by IMTM. IP10.C8 regulates the growth and differentiation of sebocytes as well as keratinocytes and is a potent inhibitor of the local inflammatory reaction. Moreover, the substance acts bacteriostatically against *Propionibacterium acnes*. By targeting these major pathogenetic factors of the disease, it is anticipated a promising alternative of current therapeutic options in Acne.

IMTM has developed PETIR™ (Peptidase Targeted Immune Regulation) as a novel therapeutic platform for the treatment of chronic inflammation, allergies and autoimmune diseases. PETIR™ drugs are compounds combining the capability to inhibit the two target enzymes Dipeptidylpeptidase IV and Aminopeptidase N in one single chemical entity. By inhibition of both target enzymes, PETIR™ compounds initiate a highly effective decrease of the inflammatory reaction that is based on the reduction of the activation state of activated immune cells and the simultaneous re-activation of the immunosuppressive function of regulatory T cells (Treg).

On the basis of its pipeline IMTM plans to bring further PETIR™ compounds into clinical development continuously in the coming years to combat chronic inflammation. Therefore, IMTM acknowledges the initiation of this Phase I trial as an important milestone during the realization of its demanding goals.